Pravastatin for the prevention of preeclampsia in high-risk pregnant women

Keyphrases

• Atorvastatin 100%
• Preeclampsia Prevention 100%
• High-risk Pregnant Women 100%
• Preeclampsia 50%
• Statins 33%
• Inflammation 16%
• Pharmacology 16%
• Oxidative Stress 16%
• Risk Factors 16%
• Obstetrics 16%
• Pharmacokinetics 16%
• Beneficial Effects 16%
• Non-pregnant Women 16%
• Safety Profile 16%
• Reductase Inhibitors 16%
• Cardiovascular Events 16%
• Human Pregnancy 16%
• Pharmacokinetic Profile 16%
• Neonatal Morbidity 16%
• Maternal-fetal 16%
• Endothelial Injury 16%
• Maternal Morbidity 16%
• Safety Data 16%
• Children's Health 16%
• Human Development 16%
• Health Development 16%
• Widespread Adoption 16%
• Exposure Data 16%
• Cardiovascular Mortality 16%
• Kennedy 16%
• 3-hydroxy-3-methylglutaryl-CoA Reductase 16%
• Pregnancy Exposure 16%
• Daily Treatment 16%
• Teratogenicity 16%
• Pathophysiologic Pathways 16%
• Angiogenic Imbalance 16%
• Adult Cardiovascular Disease 16%
• Fetal Safety 16%
• Biological Plausibility 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Preeclampsia 100%
• Pravastatin 100%
• Pharmacokinetics 33%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 33%
• Inflammation 16%
• Cardiovascular Disease 16%
• Newborn Morbidity 16%
• Oxidoreductase 16%
• Endothelium Injury 16%
• Maternal Morbidity 16%
• Cardiovascular Mortality 16%
• Coenzyme A 16%
• Teratogenicity 16%